We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Researchers at Introgen Therapeutics, along with their collaborators at The
University of Texas M. D. Anderson Cancer Center, have published new findings
on the role of IL-24 in regulating the immune system in the current online issue
of the Journal of Leukocyte Biology.
OSI Pharmaceuticals has initiated a Phase I clinical study of PSN357. PSN357 is a glycogen phosphorylase inhibitor, which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.
Nabi Biopharmaceuticals has initiated the first human clinical study for a vaccine being developed to prevent Staphylococcus aureus type 336 infections in at-risk patients.
NanoBio has completed its Phase II study of NB-001 in patients with herpes labialis (cold sores) and is moving ahead with plans to conduct Phase III clinical trials next year.
Aastrom Biosciences announced that it has expanded the U.S. Phase I/II clinical trial of its adult stem cell-based Tissue Repair Cells (TRCs) in the treatment of severe long bone open or non-union fractures to include the University of Nebraska Medical Center (UNMC) in Omaha, Neb.
Dendreon has announced that the analysis of the final three-year survival data of its second Phase III study of Provenge-an investigational active immunotherapy for the treatment of prostate cancer-showed a survival benefit in men with advanced prostate cancer who were treated with Provenge.
Viral Genetics, a drug development company developing a biologic therapy for HIV infection, announced that the eight-week, 16-injection treatment phase of its ongoing South African study is completed for all enrolled patients.
The FDA has granted tentative approval to Teva Pharmaceutical's abbreviated new drug application for tramadol and acetaminophen tablets in a 37.5 mg/325 mg dose.